AstraZeneca halts lung cancer study in latest blow to pipeline

AstraZeneca (AZN) has discontinued a late-stage lung cancer trial involving its experimental immunotherapy volrustomig, marking the latest in a series of clinical and regulatory setbacks that have raised questions about the depth of the UK drugmaker's pipeline.

The company said an independent data monitoring committee recommended terminating the Phase III study after concluding that a combination of volrustomig and chemotherapy was unlikely to outperform Merck's (MRK) blockbuster immunotherapy Keytruda when paired with chemotherapy. The trial had been evaluating the treatment in a form of lung cancer and was not expected to meet its primary endpoints of improving overall survival or delaying disease progression.

The decision adds to a difficult period for AstraZeneca, which has suffered several high-profile disappointments in recent months. Investors have been unsettled by the failure of Wainua in a late-stage cardiovascular study, a regulatory setback for breast cancer treatment camizestrant in the US, and a Phase III failure for rare disease drug Ultomiris.

Despite the latest setback, AstraZeneca sought to reassure investors by simultaneously reporting positive data from two separate late-stage lung cancer studies. The company's Tagrisso-Orpathys combination met key study goals, while Enhertu, its antibody-drug conjugate developed with Daiichi Sankyo (4568.T), also delivered positive results.

The mixed update was enough to lift AstraZeneca shares by about 1 per cent, partially offsetting a decline that has seen the stock lose more than 16 per cent of its value so far this year.

Management played down the commercial significance of the discontinued study. According to the company, the trial represented roughly 20 per cent of volrustomig's estimated peak sales potential and does not alter AstraZeneca's ambition to generate $80bn of annual revenue by 2030. The group had previously projected peak annual sales of more than $5bn for the drug.

Analysts also stressed that the latest result does not close off the broader opportunity for volrustomig. Citi analyst Graham Parry said the lost indication could be offset by several ongoing Phase III programmes. AstraZeneca confirmed that late-stage trials in cervical cancer, head and neck squamous cell carcinoma, and mesothelioma will continue as planned.

For investors, the focus is increasingly shifting towards upcoming clinical catalysts. Markus Manns, portfolio manager at Union Investment and a shareholder in AstraZeneca, described the latest results as incremental rather than transformative, noting that all three studies involved relatively small indications. He argued that forthcoming data from the Avanzar and Serena-4 programmes would have a greater influence on market sentiment.

The drugmaker's shares have faced pressure from more than clinical disappointments. Earlier this month, reports of potential merger discussions involving Bristol Myers Squibb (BMY) triggered volatility in the stock and reignited debate over AstraZeneca's strategic direction.

Nevertheless, the company continues to maintain confidence in its long-term growth outlook. When reporting second-quarter results in July, AstraZeneca reaffirmed its guidance and reiterated plans to reach $80bn in annual sales by the end of the decade. Central to that target is a pipeline expected to deliver as many as 20 new product launches over the coming years.

Susan Galbraith, AstraZeneca's head of oncology and haematology research and development, acknowledged the disappointment of the trial outcome but said the company would apply lessons from the study to future programmes. AstraZeneca added that no new safety concerns emerged during the trial, with the combination's safety profile remaining consistent with those of the individual medicines.

Volrustomig is one of AstraZeneca's most closely watched next-generation immuno-oncology assets. The bispecific antibody is designed to target both PD-1 and CTLA-4, two immune checkpoints that cancers exploit to evade detection by the body's immune system. While the latest trial outcome narrows the drug's commercial opportunity, investors will now look to the remaining late-stage studies to determine whether volrustomig can still become a meaningful contributor to AstraZeneca's oncology franchise.